Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Clasificar por
Keyphrases
Latin America (LATAM)
38%
Colombian Patients
38%
Colombian
38%
Schizophrenia
35%
Colombia
34%
COVID-19
28%
Patients with Schizophrenia
28%
Early-onset Schizophrenia
23%
Clinical Outcomes
22%
Healthy Controls
20%
Hospitalization
19%
Psychiatrists
19%
Treatment-resistant Depression
19%
Risperidone Long-acting Injection
19%
Schizophrenia Treatment
19%
Prospective Observational Study
19%
Treatment Impact
19%
Psychiatric Assessment
19%
Toxoplasma Gondii Infection
19%
Schizophrenia Spectrum Disorders
19%
Tear Gas
19%
Virus
19%
Medication Adherence
19%
Consensus Guidelines
19%
Schizophrenic
19%
Esketamine Nasal Spray
19%
Neurovascular Structures
19%
Mental Health
19%
Delphi Panel
19%
Adverse Drug Event Reporting
19%
Absolute Neutrophil Count
19%
Treatment Consensus
19%
Clozapine Treatment
19%
Psychopharmacological Treatment
19%
Group of People
15%
Retinal Structure
15%
Years of Potential Life Lost
15%
Private Practitioners
12%
Mental Health Services
12%
Clozapine
12%
Remote Provision
12%
Delphi
12%
Paliperidone Palmitate Long-acting Injection
11%
Global Assessment of Functioning
11%
Social Performance
11%
Individual Performance
11%
Schizoaffective Disorder
10%
Antipsychotics
9%
Accurate Diagnosis
9%
Doctor-patient Relationship
9%
Medicine and Dentistry
Schizophrenia
57%
Cohort Analysis
38%
Mental Health
38%
Diagnosis of Schizophrenia
34%
Diseases
31%
Patient Compliance
25%
Clozapine
19%
Disease Predisposition
19%
Doctor Patient Relation
19%
Virus
19%
Severe Mental Illness
19%
Adverse Drug Reaction
19%
Program Impact
19%
Treatment Resistant Depression
19%
Risperidone
19%
Tear Gas
19%
Nasal Spray
19%
Esketamine
19%
Psychopharmacological Treatment
19%
Absolute Neutrophil Count
19%
COVID-19
19%
Psychiatry
19%
Mental Disorder
19%
Global Assessment of Functioning
17%
Injection
15%
Antipsychotic
12%
Quality of Life
12%
Polypharmacy
12%
Clinical Global Impression
11%
Selective Serotonin Reuptake Inhibitor
9%
Substance Use
9%
Reuptake Inhibitor
9%
Bipolar Depression
9%
Drug Therapy
6%
Population Health
6%
Clinical Genetics
6%
Schizoaffective Disorder
6%
Family Issue
6%
Social Isolation
6%
Bipolar Disorder
6%
Psychiatric Rehabilitation
6%
Addictive Behavior
6%
Adolescence
6%
Treatment-Resistant Schizophrenia
6%
Nutritional Status
6%
Anxiety Disorder
6%
Social Psychiatry
6%
Psychopharmacology
6%
Mood Stabilizer
6%
Disease Severity
6%
Pharmacology, Toxicology and Pharmaceutical Science
Schizophrenia
100%
Risperidone
57%
Cohort Study
38%
Quetiapine
27%
Remission
22%
Psychosis
22%
Diseases
21%
Toxoplasma
19%
Esketamine
19%
Nasal Spray
19%
Clozapine
19%
Bipolar I Disorder
19%
Toxoplasmosis
19%
Disease Predisposition
19%
Paliperidone
19%
Placebo
19%
Treatment Resistant Depression
19%
Adverse Drug Reaction
19%
Recurrent Disease
14%
Olanzapine
10%
Antipsychotic
9%
Parasite
9%
Selective Serotonin Reuptake Inhibitor
9%
Reuptake Inhibitor
9%
Pathophysiology
9%
Toxoplasma gondii
9%
Case-Control Study
9%
Immunoglobulin G
9%
Prevalence
9%
Treatment-Resistant Schizophrenia
7%
Polypharmacy
7%
Observational Study
5%
